Ipca Laboratories Ltd (IPCALAB)
₹1,927.80
Mkt cap
₹48,869 Cr
P/E ratio
35.60
P/B
6.06
Div yield
0.31%
ROE
15.70%
ROCE
17.00%
EPS (TTM)
₹54.15
Book value
₹318
52W range
1,252–2,038
Sector
Healthcare
Price history
Previous close
Ipca Laboratories is an integrated pharmaceutical company manufacturing branded and generic formulations, APIs and intermediates. Indian branded formulations are its core profit engine, complemented by formulation exports across Europe, Africa, the Americas, Asia, CIS and Australasia. The consolidated business includes Unichem Laboratories and its US, Brazil, Europe and South Africa operations. [1]
NSE IPCALABBSE 524494
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−5.41% from high₹1,928
₹1,252+54.03% from low₹2,038
Current
₹1,927.80
Prev close
₹1,925.00
Day
+0.15%
Price performance
1D
+0.15%
1W
−1.31%
1M
−0.53%
3M
+9.61%
6M
+25.01%
1Y
+50.99%
YTD
+37.31%
Financials
Revenue, profit & margin
P/E ratio
35.6×
IPCALAB is 3% above the sector median of 34.5×
IPCALAB35.6×
Sector median34.5×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 | |
| Expenses | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 | |
| Operating Profit | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 | |
| OPM % | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% | 22% | 20% | 24% | |
| Other Income | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 | |
| Interest | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 | |
| Depreciation | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 | |
| Profit before tax | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 | |
| Tax % | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% | 18% | 24% | 26% | |
| Net Profit | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 | |
| EPS in Rs | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.07% · closed higher next day 35 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23◦ | 14 Feb '24◦ | 29 May '24◦ | 13 Aug '24◦ | 14 Nov '24◦ | 13 Feb '25◦ | 29 May '25◦ | 11 Aug '25 | 13 Nov '25 | 13 Feb '26 | 29 May '26 | 13 Aug '26 |
| Earnings day | +0.35% | −0.20% | −3.45% | −3.42% | +1.96% | −1.81% | −3.07% | −3.61% | −2.90% | +0.85% | −3.05% | −3.46% |
| +1 day | +0.63% | +7.51% | −10.96% | −4.22% | +2.47% | −0.95% | −3.69% | −0.73% | +10.34% | +1.51% | −5.21% | +4.92% |
| +5 days | +2.30% | +6.58% | −10.22% | +0.44% | +1.93% | −3.08% | −6.74% | −0.24% | +7.26% | −1.57% | +4.42% | +6.40% |
| +15 days | +7.21% | +2.84% | −12.18% | +3.39% | −0.14% | −10.99% | −7.86% | −2.51% | +8.48% | +2.02% | +0.85% | +9.41% |
| +30 days | +4.66% | +6.83% | −5.44% | +5.88% | +10.18% | −5.03% | −1.39% | −2.77% | +7.38% | +2.40% | +15.96% | +6.85% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202644.72%Promoter
Promoters44.72%
FIIs11.53%0.81
DIIs36.60%0.44
Public7.15%0.04
Government0.00%0.32
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,761.00 | 33.45 | 4,22,523 | 0.91% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,664.00 | 86.11 | 2,56,549 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,580.00 | 80.24 | 1,74,208 | 0.83% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,244.00 | 90.49 | 1,21,246 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,184.40 | 24.27 | 1,18,144 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,345.00 | 40.10 | 1,12,265 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,358.00 | 35.33 | 1,09,709 | 0.96% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Ipca Labs. | ₹1,926.20 | 35.58 | 48,869 | 0.31% | 424 | +72.33% | 2,788 | +20.76% | 16.98% |
| Median: 159 Co. | ₹439.10 | 34.49 | 1,934 | 0.08% | 14 | +22.88% | 170 | +18.91% | 15.11% |
Filings
Annual reports13
Concall transcripts39
TranscriptAug 2026RECAug 2026TranscriptJun 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025RECNov 2025TranscriptAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024TranscriptJun 2024TranscriptFeb 2024TranscriptNov 2023TranscriptAug 2023TranscriptApr 2023TranscriptFeb 2023TranscriptNov 2022TranscriptAug 2022TranscriptMay 2022
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 OctBoard Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2026 22 Oct - Board meets on 5 Nov 2026 to consider Q2 and half-year unaudited financial results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - Submitted Regulation 74(5) certificate for quarter ended September 30, 2026.Closure of Trading Window 22 SepAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 17 Aug - Ipca Q1 FY27 call: 13% domestic growth, 21% consolidated growth, guidance raised to 14-16% and 23% margin.